Shares of Ocera Therapeutics Inc (NASDAQ:OCRX) have been assigned an average recommendation of “Hold” from the six research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $4.19.

Several research analysts have recently commented on the stock. Cowen restated a “buy” rating and set a $11.00 price target on shares of Ocera Therapeutics in a research note on Monday, December 18th. Zacks Investment Research lowered shares of Ocera Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 8th. Finally, HC Wainwright lowered shares of Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 target price on the stock. in a research note on Friday, November 3rd.

A hedge fund recently raised its stake in Ocera Therapeutics stock. Virtu KCG Holdings LLC boosted its position in Ocera Therapeutics Inc (NASDAQ:OCRX) by 194.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 213,531 shares of the biopharmaceutical company’s stock after buying an additional 141,040 shares during the quarter. Virtu KCG Holdings LLC owned approximately 0.81% of Ocera Therapeutics worth $248,000 at the end of the most recent reporting period. 17.69% of the stock is owned by institutional investors.

Shares of Ocera Therapeutics (NASDAQ:OCRX) traded up $0.02 on Friday, hitting $1.79. 969,300 shares of the stock traded hands, compared to its average volume of 1,105,401. Ocera Therapeutics has a 52 week low of $0.52 and a 52 week high of $2.95. The firm has a market cap of $47.46, a price-to-earnings ratio of -1.85 and a beta of 2.46.

Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.24). equities research analysts forecast that Ocera Therapeutics will post -0.93 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Ocera Therapeutics Inc (OCRX) Receives Consensus Recommendation of “Hold” from Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at

About Ocera Therapeutics

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Analyst Recommendations for Ocera Therapeutics (NASDAQ:OCRX)

Receive News & Ratings for Ocera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics and related companies with's FREE daily email newsletter.